Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anisole SCHEMBL28094109 | 0.92 | MAPT (0.65) | L3MBTL1MAPTFFAR1SMN1; SMN2MEN1 | |
| SCHEMBL8029095 | 0.90 | PDE4B (0.64) | L3MBTL1MAPTFFAR1SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL8981950 | 0.89 | PDE4B (0.62) | L3MBTL1MAPTFFAR1SMN1; SMN2MEN1 | |
| SCHEMBL15176983 | 0.89 | PPARA (0.65) | L3MBTL1MAPTFFAR1MTNR1AMTNR1B | |
| SCHEMBL1801957 | 0.87 | PPARA (0.68) | L3MBTL1MAPTFFAR1ALDH1A1PDE4B | |
| SCHEMBL8483507 | 0.87 | PPARA (0.68) | L3MBTL1MAPTFFAR1ALDH1A1PDE4B | |
| SCHEMBL4298103 | 0.87 | PPARA (0.68) | L3MBTL1MAPTFFAR1ALDH1A1PDE4B | |
| SCHEMBL9559951 | 0.85 | CYP1A2 (0.62) | L3MBTL1MAPTFFAR1SMN1; SMN2NPC1 | |
| SCHEMBL1806524 | 0.84 | L3MBTL1 (1.00) | L3MBTL1FFAR1MEN1NPC1ALDH1A1 | |
| SCHEMBL22578056 | 0.84 | MCL1 (0.61) | L3MBTL1MAPTFFAR1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6682766-B2 | FULL FLAVOR | THE PROCTER & GAMBLE COMPANY | 2004-01-27 | — | — | US | claimed |
| EP-1041898-B1 | BEVERAGE COMPRISING AN EFFECTIVE AMOUNT OF A SWEETNESS CUTTING COMPOSITION | PROCTER & GAMBLE (US) | 2003-05-02 | — | — | EP | claimed |
| EP-1041898-A1 | BEVERAGE COMPRISING AN EFFECTIVE AMOUNT OF A SWEETNESS CUTTING COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999027804-A1 | BEVERAGE COMPRISING AN EFFECTIVE AMOUNT OF A SWEETNESS CUTTING COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-10 | — | — | WO | claimed |
| US-5631038-A | COMPOUNDS (TASTANDS) TO REDUCE OR ELIMINATE A BITTER OR METALLIC TASTE ARE ADDED TO FOODS CONTAINING SODIUM CHLORIDE | BIORESEARCH, INC. (US) | 1997-05-20 | — | — | US | claimed |
| EP-0661932-A4 | SPECIFIC EATABLE TASTE MODIFIERS. | BIORESEARCH INC (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0661932-A1 | SPECIFIC EATABLE TASTE MODIFIERS | BIORESEARCH, INC. (US) | 1995-07-12 | — | — | EP | claimed |
| WO-1993010677-A1 | SPECIFIC EATABLE TASTE MODIFIERS | BIORESEARCH, INC. (US) | 1993-06-10 | — | — | WO | claimed |
| EP-4626865-A1 | CYCLIC PYRAZOLE DIAMIDE IRE1/XBP1S ACTIVATORS | Protego Biopharma, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024118810-A1 | CYCLIC PYRAZOLE DIAMIDE IRE1/XBP1S ACTIVATORS | PROTEGO BIOPHARMA, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-11858876-B2 | CCL2 inhibitors | LAPKO INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-5059609-A | Lipoxygenase inhibitors; leukotriene receptor blockers; psoriasis; antiulcer agents and myocardial infarctions | PFIZER INC. (US) | 1991-10-22 | — | — | US | disclosed |
| WO-1990012010-A1 | SUBSTITUTED CHROMANS IN THE TREATMENT OF ASTHMA, ARTHRITIS AND RELATED DISEASES | PFIZER INC. (US) | 1990-10-18 | — | — | WO | disclosed |
| EP-0391625-A1 | Substituted chromans in the treatment of asthma, arthritis and related diseases | PFIZER INC. (US) | 1990-10-10 | — | — | EP | disclosed |
| WO-1989003681-A1 | SUBSTITUTED TETRALINS, CHROMANS AND RELATED COMPOUNDS IN THE TREATMENT OF ASTHMA | PFIZER INC. (US) | 1989-05-05 | — | — | WO | disclosed |
| EP-0313296-A2 | Substituted chromans and related compounds in the treatment of asthma | PFIZER INC. (US) | 1989-04-26 | — | — | EP | disclosed |
| EP-0313295-A2 | Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases | PFIZER INC. (US) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885MAPT 4264/4885FFAR1 147/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885MAPT 4264/4885FFAR1 147/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885MAPT 4264/4885FFAR1 147/4885 |
| US-11858876-B2 | CCL2 inhibitors | CCL2, CCL11, CCR2 | L3MBTL1 2730/4885MAPT 1328/4885FFAR1 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.